Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic

Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bueno, Fernanda, Abelleira, Erika, von Stecher, Florencia, Paes de Lima, Andrea, Pitoia, Fabián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065318/
https://www.ncbi.nlm.nih.gov/pubmed/33587835
http://dx.doi.org/10.20945/2359-3997000000325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065318/
https://www.ncbi.nlm.nih.gov/pubmed/33587835
http://dx.doi.org/10.20945/2359-3997000000325

Ejemplares similares